Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom
Authors:
- BURQOL-RD Research NetworkBNBURQOL-RD Research Network
- Aris AngelisAAAris Angelis
- Panos KanavosPKPanos Kanavos
- Julio López-BastidaJLJulio López-Bastida
- Renata LinertováRLRenata Linertová
- Elena NicodENElena Nicod
- Pedro Serrano-AguilarPSPedro Serrano-Aguilar
Open Access
- 1 June 2015
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 15 (1) , 1-8
Abstract
This study aimed to determine the societal economic burden and health-related quality of life (HRQOL) of cystic fibrosis (CF) patients in the UK. A bottom-up cost-of-illness, cross-sectional, retrospective analysis of 74 patients was conducted aiming to estimate the economic impact of CF. Data on demographic characteristics, health resource utilisation, informal care, productivity losses and HRQOL were collected from questionnaires completed by patients or their caregivers. HRQOL was measured with the EuroQol 5-domain (EQ-5D) instrument. Using unit costs for 2012 we found that the average annual cost for a CF patient was €48,603, with direct health care costs amounting to €20,854 (42.9 % of total costs), direct non-health care costs being €21,528 (44.3 %) and indirect costs attributable to productivity losses being €6,222 (12.8 %). On average, the largest expenditures by far were accounted for by informal care (44.1 %), followed by medications (14.5 %), acute hospitalisations (13.9 %), early retirement (9.1 %) and outpatient and primary health care visits (7.9 %). Sharp differences existed depending on whether CF patients were in need of caregiver help (€76,271 versus €26,335). In adult CF patients, mean EQ-5D index scores were 0.64 (0.93 in the general population) and mean EQ-5D visual analogue scale scores were 62.23 (86.84 in the general population); among caregivers, these scores were 0.836 and 80.85, respectively. Our analysis highlights the importance of the economic and quality of life consequences of CF from a societal perspective. The results highlight that beyond conventional costs such as acute hospitalisations, medication and outpatient and primary care visits, indirect costs related to informal care and early retirement, have significant societal implications. Similarly, our analysis showed that the average EQ-5D index score of adult CF patients was significantly lower than in the general population, an indication that a methodological bias may exist in using the latter in economic analyses. CF poses a significant cost burden on UK society, with non-health care and indirect costs representing 57 % of total average costs, and HRQOL being considerably lower than in the general population.Keywords
This publication has 30 references indexed in Scilit:
- Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD studyHealth Policy, 2012
- Cost of Illness of Cystic Fibrosis in GermanyPharmacoEconomics, 2012
- Health-related quality of life of Spanish children with cystic fibrosisQuality of Life Research, 2012
- Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in GermanyBMC Pediatrics, 2009
- Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literatureExpert Opinion on Pharmacotherapy, 2008
- Social economic costs and health‐related quality of life in patients with degenerative cerebellar ataxia in SpainMovement Disorders, 2008
- Cystic FibrosisNew England Journal of Medicine, 2005
- ADHD: the factsArchives of Disease in Childhood, 2005
- Reliability, Validity and Reference Values of the Zarit Burden Interview for Assessing Informal Caregivers of Community-Dwelling Older Persons with DementiaCanadian Journal on Aging / La Revue canadienne du vieillissement, 2000
- The Barthel ADL Index: A reliability studyInternational Disability Studies, 1988